Leading the Way in Discovering Novel Treatments for Pancreatic Cancer
Commitment to Research
The LaBahn Pancreatic Cancer Program supports internationally recognized specialists who provide a wealth of knowledge and experience in pancreatic cancer treatment and research. We are committed to developing the next generation of medical researchers and to translating our research into cutting-edge treatments for our patients. We are involved in many areas of research, including basic science, outcomes assessments, and international clinical trials. Our dedication to research is one of the many tools we have available to make MCW a destination for the best pancreatic cancer care possible.
About our Biorepository
Our biorepository is a phenomenal resource for both translational research collaborations as well as clinical outcomes research. The Ronald Burklund Eich integrated biorepository and database captures longitudinal samples from patients across a broad spectrum of disease, from pancreatic cancer screening to diagnosis, and even post-mortem.
Basic and Translational Scientific Investigators
Scientific investigators are discovery-drivers, working to uncover more innovative and cutting-edge treatments with every study they conduct.
Michael B. Dwinell, PhD
Professor; Founding Director, Center for Immunology; Director, Bobbie Nick Voss Laboratory for Colon Cancer Research; Hanis-Stepka-Rettig Endowed Chair in Cancer Research
Cancer Metastasis, Tumor Microenvironment, Mucosal Inflammation
Guan Chen, MD, PhD
Professor
Gwen Lomberk, PhD
Chief, Division of Research; Director, Basic Science Research; Department of Surgery; Professor of Surgery and Pharmacology & Toxicology
Nikki K. Lytle, PhD
Assistant Professor
Subramaniam Malarkannan, PhD
Professor and Gardetto Chair for Immunology and Immunotherapy; Professor, Medicine (Hematology and Oncology) and Microbiology & Immunology; Senior Investigator, Versiti Blood Research Institute
NK cell development and function
Thomas McFall, PhD
Assistant Professor
I am interested in experimental-systems approaches that enable mechanism-based inference in genomic medicine and can help identify patients for selective therapeutic strategies.
Jong-In Park, PhD
Professor
Raul A. Urrutia, MD
Professor, Department of Surgery; Director, Linda T. and John A. Mellowes Center for Genomic Sciences and Precision Medicine
Research Lab Links and More
-
Department of Surgery- Division of Research
Learn More -
Dr. Dwinell's Lab Page
Learn More -
Dr. Lomberk's Lab Page
Learn More -
Dr. Park's Lab Page
Learn More -
Dr. Urrutia's Lab Page
Learn More
Recent Publications
-
(Buradagunta CS, Arsang-Jang S, Massat B, Thapa B, Patek V, D'Souza A, Auer P, Urrutia R, Janz S, Dhakal B, Hari P, Dong J.) Leukemia. 2024 Feb;38(2):383-385 PMID: 37919604 SCOPUS ID: 2-s2.0-85175540732 11/03/2023
-
Gait speed is a biomarker of cancer-associated cachexia decline and recovery.
(Roy I, Binder-Markey B, Sychowski D, Willbanks A, Phipps T, McAllister D, Bhakta A, Marquez E, D'Andrea D, Franz C, Pichika R, Dwinell MB, Jayabalan P, Lieber RL.) bioRxiv. 2023 Nov 15 PMID: 38014165 PMCID: PMC10680669 11/28/2023
-
(Jorge SD, Chi YI, Mazaba JL, Haque N, Wagenknecht J, Smith BC, Volkman BF, Mathison AJ, Lomberk G, Zimmermann MT, Urrutia R.) Front Genet. 2023;14:1291307 PMID: 38090150 PMCID: PMC10715303 SCOPUS ID: 2-s2.0-85179362461 12/13/2023
-
eIF5A-Independent Role of DHPS in p21CIP1 and Cell Fate Regulation.
(Becker AE, Wu PK, Park JI.) Int J Mol Sci. 2021 Dec 07;22(24) PMID: 34947982 PMCID: PMC8707118 SCOPUS ID: 2-s2.0-85120635476 12/25/2021